We are yet to define what the key mediators directing differental STING signaling outcomes between mouse and human pDCs are, however elucidating these molecular differences could lend insight into discrete mechanisms of inducing rapid pDC death, tools that could potentially be harnessed to improve cancer immunotherapies or alter viral immune responses. This evidence concerns the gene STING1 and cancer.